These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38045794)

  • 1. Osteoporosis Improved by Romosozumab Therapy in a Patient With Type I Osteogenesis Imperfecta.
    Dattagupta A; Petak S
    AACE Clin Case Rep; 2023; 9(6):209-212. PubMed ID: 38045794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of romosozumab for osteoporosis in a patient with osteogenesis imperfecta: A case report.
    Uehara M; Nakamura Y; Nakano M; Miyazaki A; Suzuki T; Takahashi J
    Mod Rheumatol Case Rep; 2022 Jan; 6(1):128-133. PubMed ID: 34491363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approach to the Patient: Pharmacological Therapies for Fracture Risk Reduction in Adults With Osteogenesis Imperfecta.
    Liu W; Lee B; Nagamani SCS; Nicol L; Rauch F; Rush ET; Sutton VR; Orwoll E
    J Clin Endocrinol Metab; 2023 Jun; 108(7):1787-1796. PubMed ID: 36658750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
    Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
    J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study.
    Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Kato Y
    Osteoporos Int; 2021 Oct; 32(10):1999-2009. PubMed ID: 33770201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early clinical effects, safety, and appropriate selection of bone markers in romosozumab treatment for osteoporosis patients: a 6-month study.
    Tominaga A; Wada K; Kato Y; Nishi H; Terayama Y; Okazaki K
    Osteoporos Int; 2021 Apr; 32(4):653-661. PubMed ID: 32979066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.
    Langdahl BL; Libanati C; Crittenden DB; Bolognese MA; Brown JP; Daizadeh NS; Dokoupilova E; Engelke K; Finkelstein JS; Genant HK; Goemaere S; Hyldstrup L; Jodar-Gimeno E; Keaveny TM; Kendler D; Lakatos P; Maddox J; Malouf J; Massari FE; Molina JF; Ulla MR; Grauer A
    Lancet; 2017 Sep; 390(10102):1585-1594. PubMed ID: 28755782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta.
    Uehara M; Nakamura Y; Takahashi J; Kamimura M; Ikegami S; Suzuki T; Uchiyama S; Yamaguchi T; Kosho T; Kato H
    Tohoku J Exp Med; 2017 Jun; 242(2):115-120. PubMed ID: 28626166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THE CLINICAL CHARACTERISTICS AND EFFICACY OF BISPHOSPHONATES IN AUDLT PATIENTS WITH OSTEOGENESIS IMPERGECTA.
    Xu XJ; Ma DD; Lv F; Wang JY; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Yu W; Li M
    Endocr Pract; 2016 Nov; 22(11):1267-1276. PubMed ID: 27482615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(20):1-180. PubMed ID: 23074491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone structure assessed by HR-pQCT, TBS and DXL in adult patients with different types of osteogenesis imperfecta.
    Kocijan R; Muschitz C; Haschka J; Hans D; Nia A; Geroldinger A; Ardelt M; Wakolbinger R; Resch H
    Osteoporos Int; 2015 Oct; 26(10):2431-40. PubMed ID: 25956285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiofrequency Echographic Multispectrometry (REMS): A New Option in the Assessment Bone Status in Adults with Osteogenesis Imperfecta.
    Caffarelli C; Al Refaie A; Mondillo C; Versienti A; Baldassini L; De Vita M; Tomai Pitinca MD; Gonnelli S
    J Imaging; 2023 Oct; 9(10):. PubMed ID: 37888317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Romosozumab Compared With Teriparatide on Bone Density and Mass at the Spine and Hip in Postmenopausal Women With Low Bone Mass.
    Genant HK; Engelke K; Bolognese MA; Mautalen C; Brown JP; Recknor C; Goemaere S; Fuerst T; Yang YC; Grauer A; Libanati C
    J Bone Miner Res; 2017 Jan; 32(1):181-187. PubMed ID: 27487526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FRAME Study: The Foundation Effect of Building Bone With 1 Year of Romosozumab Leads to Continued Lower Fracture Risk After Transition to Denosumab.
    Cosman F; Crittenden DB; Ferrari S; Khan A; Lane NE; Lippuner K; Matsumoto T; Milmont CE; Libanati C; Grauer A
    J Bone Miner Res; 2018 Jul; 33(7):1219-1226. PubMed ID: 29573473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
    Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous reshaping of vertebral fractures in an adolescent with osteogenesis imperfecta.
    Montero-Lopez R; Laurer E; Tischlinger K; Nagy D; Scala M; Kranewitter W; Webersinke G; Hörtenhuber T; Högler W
    Bone Rep; 2022 Jun; 16():101595. PubMed ID: 35693066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romosozumab Followed by Antiresorptive Treatment Increases the Probability of Achieving Bone Mineral Density Treatment Goals.
    Cosman F; Libanati C; Deignan C; Yu Z; Wang Z; Ferrari S; Beck Jensen JE; Peris P; Bertoldo F; Lespessailles E; Hesse E; Cummings SR
    JBMR Plus; 2021 Nov; 5(11):e10546. PubMed ID: 34761149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EFFECTS OF LONG-TERM ALENDRONATE TREATMENT ON A LARGE SAMPLE OF PEDIATRIC PATIENTS WITH OSTEOGENESIS IMPERFECTA.
    Lv F; Liu Y; Xu X; Wang J; Ma D; Jiang Y; Wang O; Xia W; Xing X; Yu W; Li M
    Endocr Pract; 2016 Dec; 22(12):1369-1376. PubMed ID: 27482608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.